BackPfizer Overview

Pfizer Total Assets

Latest total assets for PFE: $200B.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$201.13B
↓ 2.41% YoYΔ $-4.96B vs prior year quarter

Peer trimmed avg / median

Loading

Pfizer Total Assets History

Loading

Pfizer vs. peers: Total Assets Comparison

Loading

Pfizer Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Pfizer (PFE) FAQ

As of the most recent data (June 2026), PFE shows a total assets of $200B. That compares with $210B in the prior-year period — down 2.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PFE's total assets is now $200B (was $210B) — a 2.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Pfizer is outperforming or lagging.

Tracking PFE's total assets over time shows whether Pfizer is scaling, shrinking, or reshaping that part of the business. The current reading is $200B That compares with $210B in the prior-year period — down 2.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Pfizer's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $200B) with ownership activity and broader fundamentals.

Pfizer's total assets is $200B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.